| Grandinetti, Giuseppe |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Zhang, Ying |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects |
|
|
| Recruiting | 3 | 312 | RoW | Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999） | Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang | Advanced HBV-Related Hepatocellular Carcinoma (HCC) | 12/22 | 12/22 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
NCT06696261: A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome |
|
|
| Not yet recruiting | 3 | 342 | RoW | Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules | Tasly Pharmaceutical Group Co., Ltd | Postprandial Distress Syndrome | 06/26 | 08/26 | | |
| Recruiting | 3 | 472 | RoW | Qingzhu Granules, Qingzhu Granules Placebo | Tasly Pharmaceutical Group Co., Ltd | Gouty Arthritis | 10/25 | 10/25 | | |
| Gao, Jing |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Fu, Guosheng |
| Completed | 3 | 226 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 09/24 | 09/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events |
|
|
| Completed | 2 | 233 | Europe, Japan, US, RoW | LY3473329, Placebo | Eli Lilly and Company | Lipoprotein Disorder | 03/24 | 03/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04953117: A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease |
|
|
| Recruiting | N/A | 286 | RoW | DCB of Lepu Medical(dimeter≥2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels, Restore DEB, RESTORE Paclitaxel releasing coronary balloon catheter, DCB of Lepu Medical(dimeter<2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease | 06/22 | 04/23 | | |
NCT04179045: A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System |
|
|
| Not yet recruiting | N/A | 785 | RoW | The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System | Shanghai Bio-heart Biological Technology Co., Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease | 07/22 | 07/26 | | |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
NCT06039748: Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study |
|
|
| Not yet recruiting | N/A | 330 | NA | AngioQFA | Shenzhen Raysight Intelligent Medical Technology Co., Ltd., Renmin Hospital of Wuhan University, Yan'an Affiliated Hospital of Kunming Medical University, Sir Run Run Shaw Hospital, The Eighth Affiliated Hospital of Sun Yat-sen University, Jieyang People's Hospital | Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Coronary Stenosis, Vascular Diseases, Ischemia | 10/24 | 10/24 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Jiang, Nan |
NCT04722796: HANGZHOU Solution in Bicuspid AS Undergoing TAVR |
|
|
| Recruiting | N/A | 508 | RoW | TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution), Hangzhou solution, TAVR with Venus A plus using annular sizing and THV implantation technique, Traditional sizing strategy (Annulus based sizing strategy) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Venus MedTech (HangZhou) Inc., First Affiliated Hospital Bengbu Medical College, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Xiamen University Affiliated Cardiovascular Hospital, Guangdong People's Hospital, Zhengzhou Cardiovascular Hospital, The First Affiliated Hospital of Zhengzhou University, Hennan Provincial Chest Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Central South University, Northern Jiangsu Province People's Hospital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Qingdao University, Shanxi cardiovascular hospital, Tianjin Chest Hospital, Ning Bo First Hospital | Aortic Stenosis, Aortic Stenosis With Bicuspid Valve | 04/24 | 04/28 | | |
| liu, yin |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Xu, Jing |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT06664125: Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia |
|
|
| Recruiting | 2 | 50 | RoW | JMKX003002 will be administered orally, Sevelamer carbonate | Jemincare | Hyperphosphatemia | 06/25 | 09/25 | | |
NCT05119647: A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter |
|
|
| Completed | N/A | 124 | RoW | Thrombus Aspiration Catheter(Ton-bridgeMT) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Acute Ischemic Stroke | 08/22 | 11/22 | | |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Active, not recruiting | N/A | 5000 | Europe, Japan, US, RoW | | Medtronic Cardiac Rhythm and Heart Failure | Atrial Fibrillation | 01/28 | 01/28 | | |
| Sun, Xin |
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A |
|
|
| Completed | 3 | 176 | RoW | PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution | Tasly GeneNet Pharmaceuticals Co., Ltd | Charcot-Marie-Tooth Type 1A | 03/24 | 03/24 | | |
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 63 | RoW | SPH4336, Cadonilimab | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 05/25 | 12/25 | | |
| Singh, Balbir |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Active, not recruiting | N/A | 5000 | Europe, Japan, US, RoW | | Medtronic Cardiac Rhythm and Heart Failure | Atrial Fibrillation | 01/28 | 01/28 | | |
| Li, Chunjie |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
| Li, Chuan |
PCCM-IMPACTS, NCT04905420: The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients |
|
|
| Completed | N/A | 288538 | RoW | | AstraZeneca | Asthma, COPD, Asthma-COPD Overlap | 06/23 | 06/23 | | |
| Zhang, Nan |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Cong, Hongliang |
| Completed | 3 | 226 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 09/24 | 09/24 | | |
| Completed | 2 | 225 | RoW | Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time, Qishen Yiqi dripping pills 4 bags/time, Qishen Yiqi dripping pills placebo 4 bags/time | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Preserved Ejection Fraction | 12/24 | 12/24 | | |
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis |
|
|
| Not yet recruiting | N/A | 325 | RoW | FFR and FFRCT | CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China | Coronary Stenosis | 10/21 | 03/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Li, Yuechuan |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
| Sun, Daqiang |
NCT06080776: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations |
|
|
| Recruiting | 3 | 242 | RoW | SH-1028 tablets, Placebo SH-1028 tablets | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Non-small Cell Lung Cancer | 02/28 | 02/31 | | |
NCT05913089: A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 58 | RoW | TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 06/26 | 12/26 | | |
| Qi, Dalei |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Curcio, Antonio |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Liu, Xiaodong |
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection |
|
|
| Recruiting | 3 | 80 | RoW | Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 03/26 | 03/26 | | |
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 39 | RoW | TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 07/23 | 07/23 | | |
| Qin, JianWen |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
| Qin, Qin |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
| Zhang, Dongfeng |
NCT05772871: The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children |
|
|
| Recruiting | 4 | 402 | RoW | Huaiqihuang granule, Prednisone, Levamisole placebo, Levamisole, Huaiqihuang Granule placebo | Jianhua Zhou, LinkDoc Technology (Beijing) Co. Ltd. | Nephrotic Syndrome in Children | 09/25 | 10/25 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
